Literature DB >> 17579050

A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation.

Alessandra Aldinucci1, Gianni Gerlini, Silvia Fossati, Giulia Cipriani, Clara Ballerini, Tiziana Biagioli, Nicola Pimpinelli, Lorenzo Borgognoni, Luca Massacesi, Flavio Moroni, Alberto Chiarugi.   

Abstract

Poly(ADP-ribose) (PAR) polymerase (PARP)-1 is a nuclear enzyme regulating protein that functions by targeting PAR chains. Besides its classic role in DNA repair, PARP-1 is emerging as a key transcriptional regulator in different cell types including the immune ones. In this study, we investigated the role of PARP-1 in human dendritic cell (DC) function. We report that both PARP-1 mRNA and protein levels significantly increased during in vitro DC differentiation from monocytes. Of note, inhibitors of PARP-1 such as phenanthridinone and thieno[2,3-c]isoquinolin-5-one reduced expression of CD86 and CD83 in a concentration-dependent manner, having no effects on expression of CD80 and HLA-DR in mature DCs. In the same cultures, PARP-1 inhibitors also reduced production of IL-12 and IL-10. Addition of exogenous IL-12 to the culture medium partially restored CD86 expression in DCs exposed to PARP-1 inhibitors. In line with the role of PAR formation in NF-kappaB-dependent transactivation, we also report that phenanthridinone and thieno[2,3-c]isoquinolin-5-one impaired NF-kappaB and AP-1 subunit DNA binding activity in cellular extract of activated DCs. Finally, we show that PARP-1 inhibitors reduced the T cell allostimulatory activity of mature DCs, and that this reduction was prevented when DCs matured in the presence of PARP-1 inhibitors plus IL-12. Of note, nonproliferating T cells exposed to PARP-1 inhibitor-challenged DCs could undergo efficient proliferation when exposed to a subsequent activation stimulus such as anti-CD3 plus anti-CD-28. Together, data provide evidence for a key role of PARP-1 and poly ADP-ribosylation in DC immunocompetence and underscore the relevance of PARP-1 inhibitors to treatment of immune disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579050     DOI: 10.4049/jimmunol.179.1.305

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

2.  Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.

Authors:  L Cavone; B Peruzzi; R Caporale; A Chiarugi
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 3.  PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

Authors:  Nilufer Jasmine Selimah Fauzee; Juan Pan; Ya-lan Wang
Journal:  Pathol Oncol Res       Date:  2010-04-12       Impact factor: 3.201

4.  Impact of the Type I Interferon Receptor on the Global Gene Expression Program During the Course of Dendritic Cell Maturation Induced by Polyinosinic Polycytidylic Acid.

Authors:  Amy L Olex; William H Turkett; Kristina L Brzoza-Lewis; Jacquelyn S Fetrow; Elizabeth M Hiltbold
Journal:  J Interferon Cytokine Res       Date:  2016-04-01       Impact factor: 2.607

5.  Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells.

Authors:  Xuerui Luo; Jia Nie; Shuaiwei Wang; Zuojia Chen; WanJun Chen; Dan Li; Hui Hu; Bin Li
Journal:  J Biol Chem       Date:  2015-10-01       Impact factor: 5.157

Review 6.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.

Authors:  Vimal Selvaraj; Mangala M Soundarapandian; Olga Chechneva; Ambrose J Williams; Maxim K Sidorov; Athena M Soulika; David E Pleasure; Wenbin Deng
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

Review 8.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

9.  Poly (ADP-ribose) polymerases (PARPs) 1-3 regulate astrocyte activation.

Authors:  Nirmal K Phulwani; Tammy Kielian
Journal:  J Neurochem       Date:  2008-04-10       Impact factor: 5.372

10.  The interaction between the PARP10 protein and the NS1 protein of H5N1 AIV and its effect on virus replication.

Authors:  Mengbin Yu; Chuanfu Zhang; Yutao Yang; Zhixin Yang; Lixia Zhao; Long Xu; Rong Wang; Xiaowei Zhou; Peitang Huang
Journal:  Virol J       Date:  2011-12-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.